PETACH TIKVA, Israel, June 4, 2026, 17:04 IDT
PolyPid Ltd. shares edged higher in regular Nasdaq trading on Thursday, a muted move after the Israeli biotech completed its U.S. filing for its lead infection-prevention drug. The stock traded at $4.74, up 0.4%, after opening at $4.72 and moving between $4.69 and $4.74, with volume of about 41,800 shares; Nasdaq’s 2026 calendar lists regular weekday trading and no June 4 market closure.
The trigger is regulatory, not financial. PolyPid said it completed a New Drug Application, the formal request for U.S. marketing approval, for D-PLEX100 on a rolling review basis, meaning the application was filed in parts rather than all at once.
The company said a potential FDA decision under PDUFA, the U.S. law that sets target review timelines for many drug applications, is currently planned for the first quarter of 2027. The filing rests on the Phase 3 SHIELD II trial, a late-stage study, which PolyPid said cut surgical site infections by 60% versus standard care.
D-PLEX100 is aimed at preventing surgical site infections, or SSIs — infections that occur after an operation — in colorectal surgery. The drug delivers doxycycline at the wound site for about 30 days, with limited exposure to the rest of the body, Contagion Live reported; CEO Dikla Czaczkes Akselbrad called completion of the filing “a defining milestone.” Contagion Live
The share reaction suggests investors had already priced in part of the step. PolyPid had said in May that U.S. commercial partnership talks were in late stages, that a European Medicines Agency submission was planned for the third quarter, and that cash should fund operations into the second half of 2026; it reported a first-quarter net loss of $7.7 million and $10.9 million in cash, equivalents and short-term deposits at March 31.
Biotech exchange-traded funds — baskets of stocks that trade like ordinary shares — were firmer at the same time. The SPDR S&P Biotech ETF rose 1.7%, while the iShares Nasdaq Biotechnology ETF gained 1.7%, giving PolyPid some sector support even as its own move stayed narrow.
The stock remains below its 52-week high. Google Finance showed PYPD’s one-year range at $2.77 to $5.21, with Thursday’s quote still closer to the top than the bottom after a run tied to trial and filing progress.
But the path can still break in several places: FDA review, partner terms, financing, or hospital adoption. PolyPid’s annual filing says current SSI prevention already includes prophylactic antibiotics, antiseptic steps and wound care, and names localized-delivery companies including Pacira BioSciences and UroGen Pharma among potential competitors; a cheaper or easier approach could pressure any launch even if D-PLEX100 is approved.
The next tape-moving items are fairly plain: FDA acceptance of the application, confirmation of the review clock, a U.S. commercial partner and the planned European filing. Until one of those lands, Thursday’s quote is only a small move around a much bigger binary event.
For now, PYPD is up just a few cents. The FDA clock, not the first hour’s trade, is the story investors are left to price.
